Katarzyna Nazimek

Dr. Katarzyna Nazimek

Department of Immunology, The Jagiellonian University College of Medicine, Krakow, Poland
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KBKrzysztof Bryniarski
Krzysztof Bryniarski
WPWlodzimierz Ptak
Wlodzimierz Ptak
AJAsha Jayakumar
Asha Jayakumar
KPKerstin Püllmann
Kerstin Püllmann
MCMichael J. Caplan
Michael J. Caplan
PAPhilip Askenase
Philip Askenase

2 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KLKaren L Lankford
Karen L Lankford
EAEdgardo J Arroyo
Edgardo J Arroyo
KNKatarzyna Nazimek
Katarzyna Nazimek
KBKrzysztof Bryniarski
Krzysztof Bryniarski
PAPhilip W Askenase
Philip W Askenase
JKJeffery D Kocsis
Jeffery D Kocsis
In a previous report we showed that intravenous infusion of bone marrow-derived mesenchymal stem cells (MSCs) improved functional recovery after contusive spinal cord injury (SCI) in the non-immunosuppressed rat, although the MSCs themselves were not detected at the spinal cord injury (SCI) site [1]. Rather, the MSCs lodged transiently in the lungs for about two days post-infusion. Preliminary studies and a recent report [2] suggest that the effects of intravenous (IV) infusion of MSCs could be mimicked by IV infusion of exosomes isolated from conditioned media of MSC cultures (MSCexos). In this study, we assessed the possible mechanism of MSCexos action on SCI by investigating the tissue distribution and cellular targeting of DiR fluorescent labeled MSCexos at 3 hours and 24 hours after IV infusion in rats with SCI. The IV delivered MSCexos were detected in contused regions of the spinal cord, but not in the noninjured region of the spinal cord, and were also detected in the spleen, which was notably reduced in weight in the SCI rat, compared to control animals. DiR “hotspots” were specifically associated with CD206-expressing M2 macrophages in the spinal cord and this was confirmed by co-localization with anti-CD63 antibodies labeling a tetraspanin characteristically expressed on exosomes. Our findings that MSCexos specifically target M2-type macrophages at the site of SCI, support the idea that extracellular vesicles, released by MSCs, may mediate at least some of the therapeutic effects of IV MSC administration.

1 June 2017 in Immunobiology
Verified
Journal Article
Closed access
KNKatarzyna Nazimek
Katarzyna Nazimek
SSSpencer Strobel
Spencer Strobel
PBPaweł Bryniarski
Paweł Bryniarski
MKMichael Kozlowski
Michael Kozlowski
IFIwona Filipczak-Bryniarska
Iwona Filipczak-Bryniarska
KBKrzysztof Bryniarski
Krzysztof Bryniarski

Verified
Journal Article
Open access
PDF file
PBPaweł Bryniarski
Paweł Bryniarski
KNKatarzyna Nazimek
Katarzyna Nazimek
JMJanusz Marcinkiewicz
Janusz Marcinkiewicz
This review article is focused on antihypertensive drugs, namely angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), and their immunomodulatory properties reported in hypertensive patients as well as in experimental settings involving studies on animal models and cell lines. The immune regulatory action of ACEI and ARB is mainly connected with the inhibition of proinflammatory cytokine secretion, diminished expression of adhesion molecules, and normalization of CRP concentration in the blood plasma. The topic has significant importance in future medical practice in the therapy of patients with comorbidities with underlying chronic inflammatory responses. Thus, this additional effect of immune regulatory action of ACEI and ARB may also benefit the treatment of patients with metabolic syndrome, allergies, or autoimmune disorders.

29 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KBKrzysztof Bryniarski
Krzysztof Bryniarski
WPWlodzimierz Ptak
Wlodzimierz Ptak
EMEmilia Martin
Emilia Martin
KNKatarzyna Nazimek
Katarzyna Nazimek
MSMarian Szczepanik
Marian Szczepanik
PAPhilip Askenase
Philip Askenase
Lymph node and spleen cells of mice doubly immunized by epicutaneous and intravenous hapten application produce a suppressive component that inhibits the action of the effector T cells that mediate contact sensitivity reactions. We recently re-investigated this phenomenon in an immunological system. CD8+ T lymphocyte-derived exosomes transferred suppressive miR-150 to the effector T cells antigen-specifically due to exosome surface coat of antibody light chains made by B1a lymphocytes. Extracellular RNA (exRNA) is protected from plasma RNases by carriage in exosomes or by chaperones. Exosome transfer of functional RNA to target cells is well described, whereas the mechanism of transfer of exRNA free of exosomes remains unclear. In the current study we describe extracellular miR-150, extracted from exosomes, yet still able to mediate antigen-specific suppression. We have determined that this was due to miR-150 association with antibody-coated exosomes produced by B1a cell companions of the effector T cells, which resulted in antigen-specific suppression of their function. Thus functional cell targeting by free exRNA can proceed by transfecting companion cell exosomes that then transfer RNA cargo to the acceptor cells. This contrasts with the classical view on release of RNA-containing exosomes from the multivesicular bodies for subsequent intercellular targeting. This new alternate pathway for transfer of exRNA between cells has distinct biological and immunological significance, and since most human blood exRNA is not in exosomes may be relevant to evaluation and treatment of diseases.

27 April 2015 in Immunology
Verified
Journal Article
Closed access
PDF file
KNKatarzyna Nazimek
Katarzyna Nazimek
WPWlodzimierz Ptak
Wlodzimierz Ptak
BNBernadeta Nowak
Bernadeta Nowak
MPMaria Ptak
Maria Ptak
PAPhilip W. Askenase
Philip W. Askenase
KBKrzysztof Bryniarski
Krzysztof Bryniarski